Although DS is rare within the overall population, it occurs in up to one-quarter of patients treated with the differentiating agents, ATRA and ATO, making it a highly significant adverse drug reaction in these patients [ 7 ].
← all excerpts
Incidence of Differentiation Syndrome Associated with Treatment Regimens in Acute Myeloid Leukemia: A Systematic Review of the Literature.
1
—
—